Market Closed -
NSE India S.E.
12:43:50 10/05/2024 BST
|
5-day change
|
1st Jan Change
|
802.9
INR
|
+9.95%
|
|
+17.83%
|
+18.82%
|
Fiscal Period: March |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
44,676
|
39,940
|
82,310
|
-
|
-
|
Enterprise Value (EV)
1 |
44,676
|
38,922
|
65,153
|
79,850
|
78,927
|
P/E ratio
|
41
x
|
47.4
x
|
54.9
x
|
54.4
x
|
44.5
x
|
Yield
|
0.23%
|
0.26%
|
0.18%
|
0.14%
|
0.34%
|
Capitalization / Revenue
|
9.66
x
|
8.7
x
|
11.9
x
|
12.1
x
|
10.4
x
|
EV / Revenue
|
9.66
x
|
8.48
x
|
11.9
x
|
11.8
x
|
9.94
x
|
EV / EBITDA
|
21.9
x
|
21.4
x
|
29.5
x
|
28.9
x
|
24.2
x
|
EV / FCF
|
125
x
|
97.9
x
|
-94.1
x
|
66.6
x
|
40.4
x
|
FCF Yield
|
0.8%
|
1.02%
|
-1.06%
|
1.5%
|
2.47%
|
Price to Book
|
9.54
x
|
7.33
x
|
12.8
x
|
10.5
x
|
8.84
x
|
Nbr of stocks (in thousands)
|
101,966
|
102,071
|
102,516
|
-
|
-
|
Reference price
2 |
438.2
|
391.3
|
802.9
|
802.9
|
802.9
|
Announcement Date
|
26/05/22
|
29/05/23
|
08/05/24
|
-
|
-
|
Fiscal Period: March |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
4,624
|
4,592
|
5,478
|
6,793
|
7,942
|
EBITDA
1 |
-
|
2,037
|
1,820
|
2,209
|
2,763
|
3,265
|
EBIT
1 |
-
|
1,510
|
1,203
|
1,639
|
2,081
|
2,501
|
Operating Margin
|
-
|
32.66%
|
26.2%
|
29.92%
|
30.64%
|
31.49%
|
Earnings before Tax (EBT)
1 |
-
|
1,474
|
1,135
|
1,587
|
2,006
|
2,487
|
Net income
1 |
842.6
|
1,097
|
846.3
|
1,188
|
1,522
|
1,894
|
Net margin
|
-
|
23.72%
|
18.43%
|
21.69%
|
22.41%
|
23.84%
|
EPS
2 |
8.260
|
10.69
|
8.260
|
11.59
|
14.75
|
18.04
|
Free Cash Flow
1 |
-
|
356.5
|
397.7
|
-856.7
|
1,200
|
1,952
|
FCF margin
|
-
|
7.71%
|
8.66%
|
-15.84%
|
17.66%
|
24.57%
|
FCF Conversion (EBITDA)
|
-
|
17.5%
|
21.85%
|
-
|
43.41%
|
59.78%
|
FCF Conversion (Net income)
|
-
|
32.5%
|
46.99%
|
-
|
78.81%
|
103.06%
|
Dividend per Share
2 |
-
|
1.000
|
1.000
|
1.420
|
1.125
|
2.733
|
Announcement Date
|
05/06/21
|
26/05/22
|
29/05/23
|
08/05/24
|
-
|
-
|
Fiscal Period: March |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
1,108
|
1,162
|
1,044
|
1,207
|
1,131
|
1,210
|
1,210
|
1,369
|
1,321
|
1,493
|
EBITDA
1 |
-
|
478.3
|
478.6
|
398.9
|
487.4
|
442.9
|
491.1
|
481.2
|
553.5
|
520.2
|
608
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
237.2
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
277.1
|
252.9
|
-
|
174.5
|
233.3
|
163.6
|
274.9
|
263.8
|
311
|
277
|
308
|
Net margin
|
-
|
22.83%
|
-
|
16.72%
|
19.32%
|
14.47%
|
22.72%
|
21.8%
|
22.72%
|
20.97%
|
20.63%
|
EPS
|
2.700
|
2.460
|
-
|
1.700
|
2.270
|
1.600
|
-
|
-
|
-
|
-
|
3.000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
08/11/21
|
04/02/22
|
26/05/22
|
09/08/22
|
10/11/22
|
13/02/23
|
29/05/23
|
09/08/23
|
-
|
-
|
-
|
Fiscal Period: March |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
1,019
|
1,708
|
2,460
|
3,383
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
357
|
398
|
-857
|
1,200
|
1,952
|
ROE (net income / shareholders' equity)
|
-
|
26.5%
|
16.7%
|
19.5%
|
20.7%
|
21.3%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
45.90
|
53.40
|
62.60
|
76.20
|
90.80
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1,223
|
1,248
|
2,331
|
1,186
|
1,153
|
Capex / Sales
|
-
|
26.46%
|
27.19%
|
43.1%
|
17.46%
|
14.52%
|
Announcement Date
|
05/06/21
|
26/05/22
|
29/05/23
|
08/05/24
|
-
|
-
|
Last Close Price
802.9
INR Average target price
703.8
INR Spread / Average Target -12.35% Consensus |
1st Jan change
|
Capi.
|
---|
| +18.82% | 985M | | -16.58% | 8.49B | | +58.90% | 4.08B | | -39.78% | 2.42B | | -10.33% | 2.42B | | -8.91% | 2.33B | | -2.53% | 2.01B | | -19.90% | 1.53B | | -38.30% | 1.26B | | +2.19% | 1.07B |
Medical & Diagnostic Laboratories
|